Wealth Quarterback LLC Crispr Therapeutics Ag Transaction History

Wealth Quarterback LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$45.39 - $59.0 $7,534 - $9,794	-166 Reduced 2.06%	7,909 $358,000
Q2 2023 Aug 10, 2023	SELL	$43.47 - $67.77 $7,129 - $11,114	-164 Reduced 1.99%	8,075 $453,000
Q1 2023 May 12, 2023	BUY	$41.0 - $56.12 $1,394 - $1,908	34 Added 0.41%	8,239 $372,000
Q4 2022 Feb 10, 2023	SELL	$39.19 - $65.67 $509 - $853	-13 Reduced 0.16%	8,205 $333,000
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $13,258 - $18,180	-217 Reduced 2.57%	8,218 $537,000
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $107,729 - $183,984	2,492 Added 41.93%	8,435 $513,000
Q3 2021 Nov 17, 2021	SELL	$110.2 - $156.64 $22,591 - $32,111	-205 Reduced 3.33%	5,943 $638,000
Q2 2021 Aug 11, 2021	BUY	$100.84 - $161.89 $619,964 - $995,299	6,148 New	6,148 $996,000
Q2 2020 Aug 17, 2020	SELL	$38.5 - $76.05 $2,887 - $5,703	-75 Closed	0 $0
Q4 2019 Feb 27, 2020	BUY	$36.68 - $73.13 $2,751 - $5,484	75 New	75 $4,000
Q4 2019 Feb 18, 2020	SELL	$36.68 - $73.13 $300,482 - $599,080	-8,192 Closed	0 $0
Q1 1987 May 17, 2022	BUY	N/A	8,192	8,192 $0

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Wealth Quarterback LLC, based on Form 13F filings with the SEC.

Stay updated on Wealth Quarterback LLC with notifications on news.